Candid Therapeutics secures exclusive global rights to WuXi Biologics' tri-specific T-cell engager, with potential milestone payments reaching $925 million and first human trials planned for early 2026.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.